CLINICAL TRIALS PROFILE FOR CAPLYTA
✉ Email this page to a colleague
All Clinical Trials for CAPLYTA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05356013 ↗ | Caplyta in Borderline Personality Disorder | Not yet recruiting | Intra-Cellular Therapies, Inc. | Phase 2 | 2022-07-01 | The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies). |
| NCT05356013 ↗ | Caplyta in Borderline Personality Disorder | Not yet recruiting | University of Chicago | Phase 2 | 2022-07-01 | The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies). |
| NCT05890768 ↗ | Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine | Recruiting | University of New Mexico | Phase 4 | 2023-05-11 | This study will examine the differential relationships between antipsychotic efficacy and changes in dopaminergic and glutamatergic brain metabolism in lumateperone and risperidone treated early psychosis patients. Baseline glutamate and dopamine brain scans, and symptom severity measures will be collected, followed by repeated measures at 6 weeks. Half of the early psychosis patients will be treated with lumateperone, half with risperidone. Healthy control subejcts will also be examined once. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CAPLYTA
Condition Name
Clinical Trial Locations for CAPLYTA
Trials by Country
Clinical Trial Progress for CAPLYTA
Clinical Trial Phase
Clinical Trial Sponsors for CAPLYTA
Sponsor Name
